MDT Stock Recent News
MDT LATEST HEADLINES
Dividend stocks are finally cycling back into portfolios after a few years' worth of higher interest rates put fixed-income options ahead of dividend distribution yield for income investors. As those investors circle back toward dividend stocks, a few things have changed about how to best look at the many available offerings – but that's true for most stock segments today.
Now that it's focused on just medical technology and pharmaceuticals, Johnson & Johnson's pace of annual dividend raises could accelerate. Medtronic is the largest publicly traded medical device manufacturer, and it offers a 3.3% yield at recent prices.
Undervalued healthcare stocks are primed for a comeback this year, proving themselves as lucrative investments amidst a revitalized market. With a significant uptick in performance, the S&P 500 Health Care index soared roughly 7% year-to-date (YTD), marking a robust recovery from last year's challenges.
Medtronic is the world's largest medical device company, and it has a 46-year streak of consecutive annual dividend raises. Cigarette sales are steadily declining, but Altria Group's bottom line keeps on climbing.
Dividend stocks are an excellent source of passive income. Some dividend payers are markedly safer investments than their peers, however.
Medtronic (MDT) came out with quarterly earnings of $1.30 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $1.30 per share a year ago.
Investing in dividend stocks is generally reserved for those who prefer steady returns and low volatility over the thrill of rapid potential gains. Investors saw tech stocks explode in 2023 as artificial intelligence emerged.
Today's dividend stocks are increasingly popular in a wild reversal as top tech stocks take center stage and push market indices back to all-time highs. But that presents a prime opportunity for income investors and long-term “buy and hold” strategists.
The latest trading day saw Medtronic (MDT) settling at $86.97, representing a -0.54% change from its previous close.
Medtronic's global medical device business has supported annual dividend raises since 1978, and it's well positioned for more growth. AbbVie's lead drug fell off a patent cliff last year, but soaring sales of recently launched treatments make the stock a buy right now.